The Developmental Therapeutics Program comprises a highly collaborative effort in early phase drug development that serves as a magnet for bringing promising new anti-cancer drugs from the NCI, DF/HCC investigators and industry through the earliest phase of clinical evaluation. The Program is thus tightly integrated with Disease Programs and actively transitions drugs from early to later phase development. In addition, the Program is closely aligned with other Programs and Centers that focus on drug discovery and biomarker development, as well as aspects of cancer biology that include signal transduction, cell cycle regulation, DNA repair and immuno-oncology.
Three Specific Aims are planned over the next 5 years: (1) To conduct Phase I and I-II clinical trials of new anti-cancer agents and combinations with safety, pharmacokinetic, pharmacodynamic and preliminary efficacy endpoints; (2) To validate biomarkers for drug response, resistance, and toxicity; and (3) To provide mentoring and career development support for fellows and junior faculty in early drug development. The program has 58 members, representing six DF/HCC institutions and 11 academic departments. In 2014 peer-reviewed grant funding attributed to the Program was $3.7 million in total costs from the NCI and $0.3 million from other sponsors. During the current funding period, Developmental Therapeutics Program members published 1,364 cancer-relevant papers. Of these 28% were inter-institutional, 13% were intra-programmatic, and 59% were inter-programmatic collaborations between two or more DF/HCC members. Overall, when counted once, 27% of DF/HCC publications were inter- programmatic collaborations.
|Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609|
|McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25|
|Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233|
|Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252|
|Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62|
|Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303|
|Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296|
|Yao, Lina; Seaton, Sarah Craven; Ndousse-Fetter, Sula et al. (2018) A selective gut bacterial bile salt hydrolase alters host metabolism. Elife 7:|
|Jalbut, Marla M; Brunner, Andrew M; Amrein, Philip C et al. (2018) Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 59:988-991|
|Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187|
Showing the most recent 10 out of 411 publications